Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MST1R | Q04912 | 16/20 | 0.51 |
| ▸ | MET | P08581 | 8/20 | 0.50 |
| ▸ | KDR | P35968 | 8/20 | 0.50 |
| ▸ | AXL | P30530 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
| ▸ | LYN | P07948 | 1/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | ABL2 | P42684 | 1/20 | 0.48 |
| ▸ | FRK | P42685 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL107202 | 1.00 | MST1R (0.51) | MST1RMETKDRAXLFLT3 | |
| SCHEMBL3433426 | 0.96 | MST1R (0.48) | MST1RMETKDRAXLFLT3 | |
| SCHEMBL3433431 | 0.96 | MST1R (0.48) | MST1RMETKDRAXLFLT3 | |
| SCHEMBL29699172 | 0.91 | MST1R (0.62) | MST1RMETKDRAXLFLT3 | |
| SCHEMBL172005 | 0.91 | MST1R (0.62) | MST1RMETKDRAXLFLT3 | |
| SCHEMBL14987982 | 0.91 | MET (0.44) | MST1RMETKDRAXLFLT3 | |
| SCHEMBL14987981 | 0.91 | MET (0.44) | MST1RMETKDRAXLFLT3 | |
| SCHEMBL14987910 | 0.90 | MET (0.43) | MST1RMETKDRAXLFLT3 | |
| SCHEMBL14987909 | 0.90 | MET (0.43) | MST1RMETKDRAXLFLT3 | |
| SCHEMBL106579 | 0.88 | MST1R (0.53) | MST1RMETKDRAXLFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | WELLMARKER BIO CO., LTD. (KR) | 2023-06-08 | — | — | US | disclosed |
| US-20210317133-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2021-10-14 | — | — | US | disclosed |
| EP-3819300-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | Wellmarker Bio Co., Ltd. (KR) | 2021-05-12 | — | — | EP | disclosed |
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| EP-2426108-B1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC (CA) | 2016-08-10 | — | — | EP | disclosed |
| US-8907091-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-8846927-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20130310564-A1 | Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors | METHYLGENE INC. (CA) | 2013-11-21 | — | — | US | disclosed |
| US-8569503-B2 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | METHYLGENE INC. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-8389541-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2012-05-03 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| EP-2426108-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MethylGene Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
| EP-2183254-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | MethylGene Inc. (CA) | 2010-05-12 | — | — | EP | disclosed |
| EP-2183255-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MethylGene Inc. (CA) | 2010-05-12 | — | — | EP | disclosed |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | Mirati Therapeutics, Inc. | 2009-11-19 | — | — | US | disclosed |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | Mirati Therapeutics, Inc. | 2009-10-22 | — | — | US | disclosed |
| WO-2009026717-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009026720-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | MST1R 759/4885MET 1062/4885KDR 526/4885 |
| US-20130310564-A1 | Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors | MAP3K19, MAP3K15, MAP3K9 | MST1R 673/4885MET 916/4885KDR 535/4885 |
| US-20090286984-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MAP3K19, MAP3K9, MAP4K2 | MST1R 759/4885MET 1062/4885KDR 526/4885 |
| US-20210317133-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | MAP4K5, MAP4K2, MAP3K9 | MST1R 1696/4885MET 3677/4885KDR 1939/4885 |
| US-20090264440-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MST1R 104/4885MET 3/4885KDR 11/4885 |
| US-20230172914-A1 | BIOMARKER-BASED THERAPEUTIC COMPOSITION | KRAS, RET, NRAS | MST1R 631/4885MET 25/4885KDR 502/4885 |
| US-20120108628-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | HGF, ERBB2, MET | MST1R 104/4885MET 3/4885KDR 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.